We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
ImmunoCellular Therapeutics Announces Issuance of Key Patent for ICT-121 Cancer Vaccine
News

ImmunoCellular Therapeutics Announces Issuance of Key Patent for ICT-121 Cancer Vaccine

ImmunoCellular Therapeutics Announces Issuance of Key Patent for ICT-121 Cancer Vaccine
News

ImmunoCellular Therapeutics Announces Issuance of Key Patent for ICT-121 Cancer Vaccine

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "ImmunoCellular Therapeutics Announces Issuance of Key Patent for ICT-121 Cancer Vaccine"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The patent includes claims covering composition of matter as well as methods of use. Specifically, the claims encompass immunogens comprising a CD133 epitope and variants thereof as well as methods of using such immunogens in immunization and to elicit cytotoxic T lymphocyte responses that are specific for tumor cells expressing HLA-A2.

“This issued patent provides significant protection for ICT-121 with what we believe are broad claims, and is an important addition to ImmunoCellular’s intellectual property estate for our cancer vaccines and monoclonal antibodies,” said Andrew Gengos, ImmunoCellular Chief Executive Officer. “We believe that our growing IP asset strengthens our leadership position in the cancer immunotherapy field, and we look forward to continuing to advance our cancer immunotherapy product candidates through the development process.”

ICT-121 is a dendritic cell vaccine. CD133 is highly expressed on cancer stem cells on most solid tumors, including brain, colon, non-small cell lung, melanoma, pancreatic and breast cancers. ImmunoCellular plans to support an investigator-sponsored, 20-patient phase I trial in recurrent glioblastoma at Cedars-Sinai Medical Center.

Advertisement